Havencrest Capital Management has made a majority investment in Tekton Research
Founded in 2006 and headquartered in Austin, Texas, Tekton Research is a leading clinical trial site network partnering with global pharmaceutical companies and CROs with 23 sites across Texas, Colorado, Georgia, Kansas and Oklahoma. Tekton conducts clinical trials for a wide array of pharmaceutical and device products across several therapeutic areas, including vaccines, infectious disease, neurology, endocrinology, immunology and dermatology, among others. Tekton is a market leader in patient access, enrollment and retention due to the dedication of its superb principal investigators and clinical research coordinators. For more information, please visit www.tektonresearch.com.
Havencrest Capital Management, a Dallas-based healthcare private equity (PE) firm, is pleased to announce its majority investment in Tekton. In partnership, Havencrest and Tekton intend to expand the company’s network of talented investigators and new embedded sites, improve clinical trial access for underrepresented patient communities, grow its expertise across therapeutic areas and continue delivering high-quality data to its valued clients. Lincoln International acted as the exclusive financial advisor to Havencrest, leveraging its extensive expertise and track record in outsourced pharmaceutical services.
Tekton is a premier clinical trial network employing an integrated strategy across embedded and hybrid sites. In a high-growth market with growing demand for speed and volume of quality patients in clinical studies, the company has built a reputation of dependability, clinical expertise and patient relationships. We expect Tekton’s partnership with Havencrest to help grow the company’s network capabilities and further establish Tekton’s leading market position.
Havencrest Capital Management
Havencrest is an investment manager of healthcare-focused PE funds with approximately $600 million of assets under management. Havencrest comprises a leading team of investment professionals, operating partners and senior advisors, including many of the nation’s leading healthcare entrepreneurs, corporate executives and public policy experts. With its unique approach to partnering with founder-owned healthcare companies with EBITDA between $3 million – $15+ million, the Havencrest team has a successful track record in building leading companies that are changing the way healthcare is delivered in America. For more information, please visit www.havencrest.com.
Meet our Senior Team
View More Transactions in Healthcare
Lincoln International advised HealthEdge Investment Partners on the sale of Corridor to WellSky, a portfolio company of Leonard Green and TPG Capital
Lincoln International advised Align Capital Partners on the sale of VetEvolve to Varsity Healthcare Partners
Lincoln International advised Your Way Medicare on its sale to Accretive, a portfolio company of GTCR
Lincoln International advised Seventure and minority shareholders on the sale of TargEDys to Biocodex
Lincoln International advised KPS Capital Partners on its sale of LRE Medical to Gyrus Capital
Lincoln International advised IVC Evidensia, a portfolio company of EQT Partners, on its sale of a group of veterinary practices to Perwyn
Lincoln International advised The Anderson Group on its sale of Parkview Health Services to Flexpoint Ford
Lincoln International advised Hallmarq Veterinary Imaging, a portfolio company of August Equity, on its refinancing
Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.